Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Funny how that works.
GLTA & JMO
Bought 56K at .011 on friday. The company is worth almost nothing at this point.
nah not me. At this point I would only be a buyer at the low end if I had the cash.
Is that you slapping the ASSk silly today?
Up 110%
yes like I mentioned if I can get shares at a penny I will. But it is eerie to have so many of the management to just leave, that could be a bad sign.
I think that new toxic MM was either marking the tape for pricing conv debt shares or trying to get us to slap the 3.5 shares , LOL.
I wish him luck this month with that failed plan.
I bought a nice bunch of the .01 shares this week, Christmas came early IMHO.
I thought toxic MM share dumps were not legal when they are this late with a 10-Q, but maybe its too soon for the OTC Stop sign that kills dilution. Last time I was in one like this, it rallied 1000% on no news, because it had a stop sign, LOLOL.
I dont know what to say, I mean one could snatch up good portions of the company for so cheap. If I can raise a significant amount of cash I would do something at a penny.
I just noticed the recent 8-K, looks like a Saturday night massacre of officers/directors, except the guy that funded the company, the CEO....
10-Q is still late now, but to add to the mystery and silence, a toxic VanDamn, VNDM-MM showed up today and my bid at .01 got filled at a new all time low.
Float (OS-?) under 10 Mil shares and market cap about $360,000 and float value at $100,000 right now is just insane?
For a company with a major new rub on pain killer on Walmart store shelves?
More executives and board members leaving for greener pastures.
GLTA & JMO
I agree, just holding for now and would buy again if it went down to .02, if I had free cash. This should run at one point, they have too many irons in the fire not to and like you said they are financing the company - who would put that much in if didnt believe in the company.
Good news, STLT 10-Q is out. Awesome Venodol gross profit margin, but the revenue is pathetic so far, even seems to be down. They need to find a way to ramp up sales. The product is awesome and could be a huge winner.
Insiders/CEO seem to be paying the bills with loans, K4. Convertible debt conversion so far seems to have been 25/30 cents and higher and not much volume. Still looks like a bargain.
STLT Up 150% and no one seems to care yet, LOL.
I still want my .020 shares dag nab it!!!
My fishing nets are still deployed for more SGSI shares. Hard to understand why a stock like this gets so ignored while folks flock to dilution machines printing 10s of billions of shares to feed sheep?
That $300,000 grant they just scored and issued news on a day ago is 1/2 of the market cap at the bid.
That is just crazy undervalued. And they have revenue and sales and a product on Walmart store shelves already. In fact they had a $500,000 inventory of Venodol 6 months ago, and that went to consignment at Walmart, and did not yet show up as revenue and gross profit, was not listed as an asset on the last report.
Once again that $500,000 of Venodol at cost of $500,000, is 80% of today's market cap at .02/share with the float only about 5 mil shares as the two founders/directors/CEOs own about 80% of the OS shares.
This is a real biotech folks, most are valued at 100,000% more that STLT. Wake up peeps!! Smell the coffee!!
the Ask has backed off to 4 cents, doesnt mean there arent shares for sale in between, but that, in general, is a good sign. This will move back, I just dont know the time frame, and I'm ok with that
Another STLT patent!!!! http://www.google.com/patents/US20110118191
$STLT patents!
http://www.google.com/patents/US20150110770
Thanks for the reply, then others were also buying today, 90,000 you did not buy, so we are finally seeing volume buying by others. Most of my powder is committed here and in others already, but I will started grabbing some more here, just way too undervalued to pass up. Thanks again!!
Oh, I also think future financials will look way better, as the current one shows a huge one time hit, loss, that was a one time event, not an ongoing expense. I just reviewed the last 12 months of news, and it further confirms how way undervalued this stock is.
That is great news about your knee and friend. If I can think of someone this could help with I will give it a whirl, personally I have no aches and pains, can't complain about that. Clearly marketing and getting the word out will be key here.
Yes that's me out there buying again today 27K shares. I believe we are at the low, simply based on the enterprise value and the fact that these guys are diversified with so many opportunities in the kitty and have such high insider financing, they're not throwing good money after bad if they didnt drink the good koolaide. If the price stays here for much longer, and i can clear some cash, which could happen any day, then I'll bid like another 200 - 400K shares at this price.
STLT Venodol product exposure
http://lermagazine.com/products/venodol-analgesic
Good STLT DD here folks!!! Top to bottom of the page!!
https://www.barchart.com/story/stocks/quotes/STLT/3673369/new-chronic-pain-relief-product-venodol-now-available-for-pre-order-at-venodolcom
Seven awesome reviews on Walmart about STLT Venodol pain killer now!!!
https://www.walmart.com/ip/Venodol-Roll-on/881335784
Is CSTI using a fake ask to dilute? The ask looks paper thin? Tempted to slap it myself, but just as equally tempted to sit at .010 for my next buy. Did you read my post about how great the Venodol works? Temped to sign on as a distributor and market the hell of it online, I see no obvious efforts to promote it???
I just searched and more Venodol stuff, reviews are showing up!!
From Amazon site selling Venodol!!
customer reviews
JDS II
5.0 out of 5 starsKey To My Pain Relief
January 12, 2018
Verified Purchase
Very excited I can now buy my favorite pain reliever on Amazon! I have had troubles for years with my feet because I have high arches. Always had to wear shoes around my house with good arch support (Like Nike Shox or Reebok Zig-Techs) and was tired of it. I tried Venodol a few weeks back and by Day 3-4 my pain was completely gone. It wasn't just less painful - it was GONE. I can walk around barefoot with no pain for the first time in years.
I also have joint issues after years of numerous sports injuries and those are also gone. Best part of it all is I don't have to worry about damaging my body/liver with opiate pain killers, Advil or any other pills.
I am 33 years old and was starting to regret playing sports when I was young. Now I can look back and appreciate those times. If you have aches and pains Venodol will change your life. Give it a shot and you won't be sorry. Trust me.
Good news folks. I posted here a short while ago that I tested the STLT Venodol out on my Knee injury (Rheumatoid Arthritis flare up, a bad one, sever swelling), and it worked great, Pain gone and pan free for the day.
This week I found out a friend whose wife suffers severe pain daily from Hip replacement and even worse never damage pain from Shingles years ago, has stopped using other pain products (the best she had found over years and years of trying everything RX and other wise) and has switched to just Venodol!!!
He bought 2 dozen bottles already. I told him he better buy a truck load in case they go belly up based on the stock price, and the product vanishes. I think the full Walmart truck is loading up today!!
The product works, and works great with no side effects!!!!
Oh, an stop hoarding the cheap shares please.
Stop that!!!! You are keeping my bid at .010 from filling
Picked up another 45K at 2 cents. At this point the market cap of under $700K is absurdly low. Any significant news on any of their initiatives should start to send this up. Especially the outstanding share count really hasn't ballooned much at all over the past year+. I think this is a screaming buy at this price, but i clearly have been wrong up to now.
Bought 100K @ 2 cents the other day with some freed up funds. Whenever a stock gets so low such that doubling or quadrupling its market cap is insignificant, then it's possibly worth a gamble. Sort of a gift considering I was unable to buy in the 3 cent range not too long ago.
Nice DD post, awesome one, many thanks! Any one have any clue where the bottom is here, or why there has been no attempt to hold the stock price up?
I noticed a buying spike the last 2 days versus historical near dead volume for 5+ years on the stock. The market cap is under 1 million dollars, and they have over a 1/2 million dollars of Venodol pain killer in inventory and at Walmart, which could lead t a million+ in revenue (I hear Walmart is probably consignment, and the last 2 10-Qs seem to confirm this).
And they have multiple Biotech products in the mill.
Insiders own about 66-75% of the OS shares.
My finger is on the fat finger button right now.
Share Count as of 06/01/2018
Authorized Shares - 4,000,000,000
Outstanding Shares - 34,472,157
Float - 9,626,903 (As of 05/24/2018)
52-Wk Range
0.032 - 0.41
Legit Scientific Board attached here:
Hengli Tang, Ph.D. Florida State University
Elliot Androphy, M.D. Indiana University
Kevin Hodgetts, Ph.D. Brigham and Women’s Hospital
As of March 31, 2018, the Company had four subsidiaries: Celtic Biotech Iowa, Inc. “Celtic Iowa”, Caretta Therapeutics, LLC (“Caretta”), SMA Therapeutics, LLC (“SMA”), and Zika Therapeutics, LLC (“Zika”).
Cancer
On June 4, 2014, Celtic Biotech Iowa, Inc. acquired Celtic Biotech Limited (hereinafter "CBL"). CBL was founded in 2003 in Dublin, Ireland and is developing novel and highly specialized compounds derived from snake venom, for the treatment of solid cancers and cancer imaging.
Pain Management
Caretta Therapeutics, LLC was formed in August 2016 to develop the commercialization of over-the-counter products. Caretta holds a license agreement to develop, manufacture and sell certain products derived from snake venom that may have analgesic properties.
Zika Virus Infection
On August 19, 2016, the Company entered a Sponsored Research Agreement (the “SRA”) with the Florida State University Research Foundation (“FSURF”) starting September 1, 2016, to perform certain research, over a two-year period, related to the discovery, synthetic modification, and preclinical validation of drug-like compounds intended to treat patients with Zika virus infection. The research is being conducted under the direction of Professor Hengli Tang.
Spinal Muscular Atrophy
In October 2016, the Company entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating spinal muscular atrophy. Spinal Muscular Atrophy is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers.
Shhh, LOL I have my STLT nets out trawling here, LOL
Last 10-Q was 7 calendar days late.
they just filed for an extension, so we have a few days
$STLT OS is Shares
34,365,907 shares
and the current and ex CEOs own about 75% of those!!
$STLT Press Releases
APRIL 18, 2018 Spotlight Innovation Subsidiary Celtic Biotech Iowa Announces Results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of Cancer
MARCH 28, 2018 Spotlight Innovation Subsidiary Celtic Biotech Iowa to Present Two Posters at 2018 American Association for Cancer Research (AACR) Annual Meeting
MARCH 13, 2018 Newly Issued U.S. Patent Covers Spotlight Innovation’s Spinal Muscular Atrophy Drug Candidates
JANUARY 11, 2018 Venodol Roll-on, Spotlight Innovation’s New Analgesic Product, Now Available at Amazon.com
SEPTEMBER 27, 2017 Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product “Venodol”
AUGUST 16, 2017 Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy
JUNE 30, 2017 Spotlight Innovation Enters into Sponsored Research Agreement to Develop New Therapies for Spinal Muscular Atrophy
Read Spotlight Innovation Press Releases here
Visit the Investor Relations page
http://www.spotlightinnovation.com/
Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders.
Spotlight Innovation's OTC Chronic Pain Relief Product Venodol Roll-on Topical Analgesic
Venodol Roll-on Topical Analgesic
Spotlight Innovation subsidiary Caretta Therapeutics’ over-the-counter chronic pain relief product, Venodol Roll-on, is now available online at Venodol.com, Walmart.com and Amazon.com. Venodol Roll-on topical analgesic is formulated to provide long-lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and stubborn body aches.
$STLT web site and data on their OTC-pain killer
http://www.spotlightinnovation.com/
https://www.walmart.com/ip/Venodol-Roll-on/881335784
Is the link to $STLT Venodol pain killer
There is only 50,000 on the $STLT ask below .099/share!!!!
I just grabbed the .048 shares. Been waiting for way too long, ask is supper thin. This was at $2 a year ago, before they had an audit issue that made the 10-K late, and turned out the issue was good news, but still hurt the stock price long run as it had fallen from $2 to .3x on low volume... the OS-Float on this stock is supper small and very thinly traded, no one really watches it. But they listed a 1/2 million dollars in Venodol inventory last 10-report and pathetic $500 in sales, but if that was $500,000 cost, and Walmart etc is moving the product (by the way the rub on pain killer works awesome, I was shocked...more on that later)
So if they report a solid sales for the last 3 months via Walmart this is thin enough to run back $2/share if they pump the 10-Q news.
VNDM shorted the last rally that ran from .08 to .25
Thanks for reminder, I was a bit depressed about it and bought that 10K shares at .06 a while ago. Based on what you said I just put order in for 20K shares at .04 and was outbid by .0001 which happens sometimes to me, automated indeed. I dont have time for this crap, if I get filled, I get filled, otherwise I'll sit there
MPID Bid Price Size Time
OTCX 0.0401 20,000 12:06
ETRF 0.04 20,000 12:06
NITE 0.0336 20,000 11:55
CSTI 0.032 10,000 08:30
VNDM 0.0302 10,000 05/14
AEXG 0.02 10,000 02/14
MAXM 0.0001 10,000 07:35
CANT 0.0001 10,000 11:51
CDEL U 0 12:06
MPID Ask Price Size Time
CSTI 0.048 10,000 08:30
CANT 0.05 40,000 09:30
CDEL 0.099 18,880 12:06
NITE 0.099 10,000 05/11
AEXG 0.22 2,500 01/19
VNDM 0.22 2,500 05/14
ETRF 0.41 3,000 10:48
MAXM 200.00 1 07:35
OTCX U 0 11:41
There are two toxic debt MMs on the bid, so I think it has bottomed. No one is selling to them. There has been near zero total volume under about .06, except a few ask slaps at .047 to .06 this year. And there has been PR push or effort to help any convertible debt unload at these levels, in fact VFIN and one other is way up .25 and .22 ever since they killed the last run from .08 to .25 on the Walmart stocking Venodol news.
10-Q is due today, may be a few days late since this OTC... but if it shows massive Walmart revenue on the Venodol they could PR that and rally it back .25 for a start. Bid battle is rising this morning, is that you? I am on the bid more shares, and watching that ask that just got slapped for any news take off....
Latest filing was a disaster.
No volume.
/nuff said.
GLTA & JMO
Looks like nothing is going on with STLT. I'm trying to pick up some shares on the cheap at 6 cents, but that could be a gamble long term. Not sure what to do with this except wait it out and try to buy some low.
Hey, Ecomike How are ya! Work Harder and I are in this stock that's getting ready to run! RNVA. Come over check it out friend! :)
I had some severe knee pain earlier this week, Rheumatoid Arthritis flare up, and finally tried my bottle $STLT Venadol rub on pain killer (now sold at Walmart and Amazon).
I had tried analgesic cream hours earlier, but it still hurt more than I can stand. I try not to use any pain killers are all, because I do not want to injury a joint, and not know it or feel it.
So I finally tried the STLT Venodol, thinking I had tried the competitors CobraZol which I tried once before. Later I checked and because the CobraZol feels hot when used, and my knee did not warm up, they I discovered I had grabbed the SGSI Venodol Bottle and had used it.
Long story short, it worked very well, and very fast. And I had no pain all day that day in that knee. I was shocked at how well and fast it worked. In fact it seemed to last 2-3 days from one treatment in this case. Needless to say I am impressed. After reading the instructions that came with both products, I was disappointed and way lower expectations, as the Venodol talking about it taking daily for use for up to 90 days to get the full effect. Well in my case that was BS, it took maybe 1 hour and lasted 2-3 days. The bottle had suggested multiple treatments per day on both brands. And the Venodol said give it up to 2 weeks of use to take full effect. I was impressed in one hour.
Also I can not take NASAIDs as they make me bleed internally!!! So this stuff maybe a godsend as my RA gets worse with age.
Also, regarding the stock, I think right now is the perfect time to load up as the 10-K could be filled any minute!!! And if the revenue and sales are huge, as I suspect, this could do a 400% gap open the day after the 10-K is filled!!!
I am buying!!!
Notice just filled, annual report will be late, up to 15 days late. I was expecting this. Any more selling and I will be loading up for a bounce.
THANK YOU/ Spotlight Innovation (STLT)
0.1 ? 0.0 (0.00%)
Volume: 11,000 @ 9:30:07 AM EDT ET
Bid Ask Day's Range
0.0701 0.1 0.1 - 0.1
STLT Detailed Quote
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2020
|
Created
|
02/02/10
|
Type
|
Free
|
Moderators |
Market Value1 | $9,355,615 | a/o Aug 29, 2016 | |
Authorized Shares | 4,000,000,000 | a/o Nov 04, 2014 | |
Outstanding Shares | 15,856,974 | a/o Aug 02, 2016 | |
-Restricted | Not Available | ||
-Unrestricted | Not Available | ||
Held at DTC | Not Available | ||
Float | 2,342,931 | a/o Aug 02, 2016 | |
Par Value | 0.001 |
VStock Transfer LLC |
Shareholders of Record | 77 | a/o Aug 02, 2016 |
|
Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.
Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.
Read the press release here.
Additional information about Celtic Biotech here.
Management
Cristopher Grunewald, CEO
Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.
Dr. David Hostelley, CFO
Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.
Jeffrey Stein, Esq., Securities Counsel
Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.
Rene Erickson, Corporate Communications
Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.
Mike Reysack, Investor Relations
Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.
Special Advisor
Jerry Cirino
Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.
Partner Firms
Auditor
Transfer Agent
VStock Transfer, LLC, Woodmere, NY
Law Firms
Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |